ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Epidemiology of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in Australia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00751387
Recruitment Status : Completed
First Posted : September 12, 2008
Last Update Posted : November 30, 2010
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary:
The study is a cross sectional, epidemiology study of disease severity for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in four geographic regions in Australia (Illawarra, Sutherland, Hunter Urban and Hunter Rural).

Condition or disease
Ankylosing Spondylitis Psoriatic Arthritis Rheumatoid Arthritis

Study Type : Observational
Actual Enrollment : 559 participants
Time Perspective: Cross-Sectional
Official Title: Australian Descriptive Epidemiology Study of Severity of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) and Exposure to Biological Disease Modifying Anti-rheumatic Drugs (bDMARDs)
Study Start Date : November 2008
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009


Group/Cohort
1



Primary Outcome Measures :
  1. Proportion of rheumatoid arthritis/psoriatic arthritis/ankylosing spondylitis patients in defined disease severity categories [ Time Frame: Single visit ]

Secondary Outcome Measures :
  1. Proportion of patients exposed to biological disease modifying antirheumatic drugs [ Time Frame: Single visit ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care
Criteria

Inclusion criteria include:

Adult patients with a diagnosis of rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who have visited a primary care centre within one of the specified catchment areas for their condition within the last 24 months.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00751387


Locations
Australia
Georgetown, Australia, 2298
Miranda, Australia, 2228
Newcastle, Australia, 2300
Wollongong, Australia, 2500
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer

Responsible Party: Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier: NCT00751387     History of Changes
Other Study ID Numbers: 0881X1-4519
B1801088
First Posted: September 12, 2008    Key Record Dates
Last Update Posted: November 30, 2010
Last Verified: November 2010

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Arthritis, Psoriatic
Spondylitis
Spondylitis, Ankylosing
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Bone Diseases, Infectious
Infection
Bone Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Antirheumatic Agents